Map Home
Type / to search with text or keywords
/
keyboard shortcut: Type "/" on your keyboard for a quick search
Search button
Loading...
Loading...
Scroll left
Grants
Citations
H-Index
Patents
News
Books
Scroll right
Collapse sidebar
Data issues & feedback
Adjust height of sidebar
KMap
People
Adjust height of sidebar
KMap
Profile
Sasha Taleban
Associate Professor, Medicine - (Clinical Scholar Track)
Medicine
Full Page
Overview
Research
More
Collaboration
(11)
C. Kent Kwoh
Mutual work: 2 Proposals
Collaboration Details
Christian Bime
Mutual work: 5 Publications
Collaboration Details
Chiu-Hsieh Hsu
Mutual work: 1 Publication
Collaboration Details
Edward Bedrick
Mutual work: 1 Proposal
Collaboration Details
John Galgiani
Mutual work: 1 Proposal
Collaboration Details
Page 1 of 3
Previous page
Next page
Grants
(59)
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Study to Evaluate the Efficacy and Safety of ABX464 Once Daily for Induction Treatment in Subjects With Moderately to Severely Act
Active
·
2024
·
$533.3K / $133.3K
·
External
Principal Investigator (PI)
clinical trials,
inflammatory bowel disease,
drug efficacy,
safety evaluation,
immunomodulatory therapy
Inflammatory Bowel Disease West Case Conference
Active
·
2024
·
$20K
·
External
Principal Investigator (PI)
inflammatory bowel disease,
case conference,
gastroenterology,
medical case presentation,
treatment management
Project Title Inflammatory Bowel Disease (IBD) West Case Conference
Active
·
2024
·
$10K
·
External
Principal Investigator (PI)
inflammatory bowel disease,
case conference,
gastroenterology,
medical education,
clinical management
Project Title Inflammatory Bowel Disease (IBD) West Case Conference
Active
·
2024
·
$5K
·
External
Principal Investigator (PI)
inflammatory bowel disease,
case conference,
west,
clinical management,
gastroenterology
A Phase 2a, Double-Blind, Randomized Adaptive Design, Placebo-Controlled, Parallel Group Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Biomarkers with Oral Colon Delivery
Active
·
2024
·
$2.6K
·
External
Principal Investigator (PI)
clinical trial,
pharmacokinetics,
drug delivery,
safety assessment,
biomarkers
Page 1 of 12
Previous page
Next page
Publications
(72)
Recent
Micronutrient in Elderly Inflammatory Bowel Disease Patients are not Associated with Worse Adverse Outcomes
2024
micronutrient,
elderly,
inflammatory bowel disease,
adverse outcomes,
nutrition
S3170 JAK(1i) to the Rescue! Upadacitinib as Rescue Therapy in Acute Severe Ulcerative Colitis
2023
ulcerative colitis,
jak inhibitor,
rescue therapy,
upadacitinib,
acute severe
S887 Health-Related Social Needs Disease Activity Are Independently Associated With Moderate-to-Severe IBD-Related Disability
2023
ibd,
health social needs,
disease activity,
disability,
health research
S1081 Incidental Diagnosis of Coccidioidomycosis in Inflammatory Bowel Disease Is Less Likely Associated With Adverse Clinic Outcomes
2023
coccidioidomycosis,
inflammatory bowel disease,
incidental diagnosis,
adverse clinic outcomes,
clinic
S920 Micronutrient Deficiencies Are Not Associated With Worsened Rates of Adverse Clinical Outcomes in Older Patients With Inflammatory Bowel Disease
2023
micronutrient deficiencies,
adverse clinical outcomes,
older patients,
inflammatory bowel disease
S931 Micronutrient Deficiencies in Elderly Inflammatory Bowel Disease Are Not Associated With Worse Adverse Outcomes
2022
micronutrient deficiencies,
elderly,
inflammatory bowel disease,
adverse outcomes,
nutrition
Exacerbation of Atopic Dermatitis Associated with Ustekinumab Treatment in Crohn's Disease
2022
dermatitis,
ustekinumab,
crohn's disease,
atopic dermatitis,
treatment
Colectomy Rates Are Increasing Among Inpatients With Concomitant Ulcerative Colitis and Clostridioides difficile.
2021
surgery,
gastroenterology,
infection,
ulcerative colitis,
treatment
Stomach This: Autoimmune Atrophic Pangastritis, a Rare Type of Gastritis
2021
S2475 emsp;Exacerbation of Atopic Dermatitis Associated With Ustekinumab Treatment in Crohn rsquo;s Disease
2021
atopic dermatitis,
ustekinumab,
crohn's disease,
exacerbation,
treatment
